| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the Medical College of Wisconsin, Department of Pharmacology and Toxicology, Milwaukee, Wis.
Correspondence to Garrett J. Gross, PhD, Medical College of Wisconsin, Department of Pharmacology and Toxicology, 8701 Watertown Plank Rd, Milwaukee, WI 53226. E-mail ggross{at}mcw.edu
| Abstract |
|---|
|
|
|---|
-selective opioid agonist BW373U86 (BW, 1 mg/kg), or the GSK inhibitors, SB21 (0.6 mg/kg) or SB41(1.0 mg/kg), either 10 minutes before ischemia or 5 minutes before reperfusion. Five minutes before opioid or SB21 treatment, some rats received either the PI3K inhibitor wortmannin (15 µg/kg) or LY294002 (0.3 mg/kg) or the TOR inhibitor rapamycin (3 µg/kg). After 30 minutes of ischemia followed by 2 hours of reperfusion, infarct size was assessed. MOR, BW, SB41, and SB21 reduced infarct size compared with vehicle when administered before ischemia (42.9±2.6, 40.3±2.3, 46.6±1.6, 42.2±1.8 versus 60.0±1.1%, respectively; P<0.001) and showed similar protection when administered 5 minutes before reperfusion (43.6±2.3, 40.2±2.6, 44.8±2.8, 39.4±0.8%, respectively; P<0.001). Wortmannin, LY294002, and rapamycin were found to inhibit OIC; however, they did not abrogate SB21-induced infarct size reduction. At 5 minutes of reperfusion, both MOR and BW increased P-GSKß at Ser9 in the ischemic zone compared with vehicle (181±20, 178±15 versus 75±17 DU, respectively; P<0.05), and this effect was abrogated by prior administration of wortmannin or rapamycin in MOR-treated rats. Furthermore, no differences were seen in phosphorylation of GSK
(Ser21 or Tyr279) or phosphorylation of GSKß (Tyr216). These data indicate that OIC occurs via the phosphorylation of GSKß at Ser9 during reperfusion.
Key Words: reperfusion glycogen synthase kinase phosphatidylinositol-3 kinase target of rapamycin opioids
| Introduction |
|---|
|
|
|---|
There are two known isoforms of GSK, GSK
, and GSKß, with GSK
differing from GSKß by an N-terminal glycine-rich tail, which contributes to a difference in molecular weight between GSK
(51 kDa) and GSKß (47 kDa). The GSK isoforms are regulated by phosphorylation at Ser21 and Tyr279 for GSK
and Ser9 and Tyr216 for GSKß. Both the Ser21/9 and Tyr279/216 sites on GSK modulate function in opposing directions, with phosphorylation of Ser21/9 decreasing GSK activity and phosphorylation of Tyr279/216 increasing GSK activity.5,6 Both GSK isoforms have high basal activity and are constitutively activated due to basal phosphorylation of their respective Tyr279/216 residue, which is different than most other protein kinases that usually have low basal activity. Tyr216 phosphorylation also increases in neuronal cells 3 hours after cerebral damage and has been suggested to contribute to a proapoptotic environment.7 In contrast, growth factors and insulin have been found to phosphorylate Ser21/9 in nonmyocardial cells, which results in a decrease in GSK activity and occurs independently of Tyr279/216 phosphorylation.8,9
Negative upstream regulators of GSK in nonmyocardial cells include phosphatidylinositol-3 kinase (PI3K), protein kinase C (PKC), target of rapamycin (TOR), and mitogen-activated protein kinase (MAPK).1,10 PI3K is a pivotal mediator of lipid signaling, which generates phosphatidylinositols, second messengers that activate numerous downstream pathways by interacting with pleckstrin homology domains.11 TOR has been found to regulate p70s6 kinase and eIF-4E BP1 in parallel, which enables TOR to control protein translation.12
Previously, our laboratory demonstrated that pretreatment with several opioid agonists produced a cardioprotective effect that occurs via PKC- and MAPK-dependent pathways.13,14 However, it is unknown whether opioids produce beneficial effects when administered at reperfusion and if opioids require the activation of PI3K and TOR to reduce infarct size. It is also unknown if opioid-induced infarct size reduction occurs by modulation of Ser21/9 and/or Tyr279/216 phosphorylation of GSK.
Therefore, we determined whether opioid-induced infarct size reduction requires the PI3K and TOR pathways and if opioids reduce infarct size equally when given before ischemia or before reperfusion. Furthermore, we quantified whether opioids modulate either GSK
and GSKß at their respective Ser21/9 and Tyr279/216 phosphorylation sites during reperfusion and if this effect could be blocked by PI3K or TOR inhibitors. We also examined whether GSK inhibitors reduce infarct size when administered either before ischemia or before reperfusion and determined if a GSK inhibitor could reduce infarct size in the presence of PI3K or TOR inhibitors.
| Materials and Methods |
|---|
|
|
|---|
Pharmacological Agents
The opioid agonists used for this study were morphine sulfate (Research Biochemicals International, RBI) and BW373U86 (Ardent Pharmaceuticals). Specific inhibitors used included wortmannin (PI3K, Sigma), LY294002 (PI3K, Calbiochem), rapamycin (TOR, NCI), SB216763 (GSK, Tocris), and SB415286 (GSK, Tocris). Morphine sulfate was dissolved in water, whereas all other agents were dissolved in DMSO. All agents and vehicle were administered intravenously via the right jugular vein.
Experimental Protocols
Male Sprague-Dawley rats (250 to 300 g) were obtained from Charles River Laboratories, Wilmington, Mass. An in vivo anesthetized intact rat model was used for these experiments. The general surgical protocol and determination of infarct size have been described previously in detail.15 After surgical intervention and stabilization, rats were separated into groups.
Infarct Size Studies With Opioids
Rats (n=6 to 8 per group) were subjected to treatment with either the nonselective opioid agonist morphine (0.3 mg/kg), the selective
agonist BW373U86 (BW, 1 mg/kg) or vehicle (DMSO) 10 minutes before ischemia. Other groups were pretreated with selective blockers 5 minutes before opioid administration. These included the selective irreversible PI3K inhibitor wortmannin (15 µg/kg), the reversible PI3K inhibitor LY294002 (0.3 mg/kg), or the selective TOR inhibitor rapamycin (3 µg/kg). Morphine (0.3 mg/kg) or BW (1 mg/kg) were also administered 5 minutes before reperfusion in two additional groups.
Western Analysis of GSK
Additional experiments (n=3 to 4 per group) were performed to quantify the extent of GSK phosphorylation at Ser21/9 and Tyr279/216 in the presence of opioids or vehicle. Opioids, BW or morphine, were administered 10 minutes before ischemia, and when applicable, pharmacological inhibitors of PI3K and TOR were administered 5 minutes before opioids. Five minutes after reperfusion, hearts were excised, separated into normal and ischemic zones, homogenized in lysis buffer (50 mmol/L HEPES, 150 mmol/L NaCl, 1.5 mmol/L MgCl2, 1 mmol/L EGTA, 1% Triton X, 10% Glycerol plus 8.6 µmol/L leupeptin, 5.8 µmol/L pepstatin A, 4 mmol/L phenylmethylsulfonyl fluoride (PMSF), 0.6 µmol/L aprotinin, 4 mmol/L sodium fluoride, and 0.8 mmol/L sodium orthovanadate), and centrifuged to remove nuclei and debris at 10 000g for 15 minutes. The supernatant was collected and centrifuged at 100 000g to enrich for the cytosolic fraction. Protein concentration in the cytosolic fraction was determined by the Pierce assay. Protein (35 µg) was loaded onto 10% Tris-HCl gels and after electrophoresis (150 V, 1.5 hours), transferred to a PVDF membrane (50 V, 2 hours). Equal loading of samples was confirmed by Ponceau S staining. Membranes were blocked with 3% bovine serum albumin solution followed by probing overnight with an antibody for either P-Ser or P-Tyr for both GSK
and ß (P-Ser21/9 GSK
/ß, 1:1000, Cell Signaling, P-Tyr279/216 GSK
/ß, 1:1000, Upstate), followed by secondary antibody application (1:2500 for P-Ser21/9 GSK
/ß, 1:10 000 for P-Tyr279/216 GSK
/ß) and ECL (Amersham). Protein was detected by X-ray film and densitometry assessed by NIH image 1.62.
Infarct Size Studies With GSK Inhibitors
Rats (n=6 to 8 per group) were subjected to treatment with either the selective GSK inhibitors SB21673 (S21, 0.6 mg/kg), SB415286 (S41, 1.0 mg/kg), or vehicle (DMSO) 10 minutes before ischemia or 5 minutes before reperfusion. One of the two GSK inhibitors, SB21, was also given in the presence of the selective blockers wortmannin (15 µg/kg), LY294002 (0.3 mg/kg), or rapamycin (3 µg/kg), administered 5 minutes before GSK inhibitor administration 10 minutes before ischemia.
Statistical Measurements
All values were denoted as mean±SEM. Statistical significance was determined by performing a one-way ANOVA with Bonferronis correction for multiplicity. Values were significantly different from vehicle or groups treated with opioids alone when P<0.001 or P<0.05.
| Results |
|---|
|
|
|---|
Infarct Size Studies With Opioids
Rats treated with morphine or BW 10 minutes before ischemia produced significant and similar reductions in infarct size when compared with vehicle (Figure 1; 42.9±2.6% and 40.3±2.3% versus 60.0±1.1%, respectively; P<0.001). Wortmannin administration before either morphine or BW abolished the reduction in infarct size (Figure 1, top; 54.7±2.3% and 57.7±2.6%, respectively) with similar results obtained for LY294002 administered before morphine or BW (Figure 1, middle; 60.8±1.6% and 61.4±1.4%, respectively). Furthermore, rapamycin administration before morphine or BW also abolished the reduction in infarct size (Figure 1, bottom; 56.6±3.1% and 61.0±1.1%, respectively). Wortmannin, LY294002, or rapamycin had no effect on infarct size when administered alone as compared with vehicle (Figure 1; 57.0±2.1%, 60.5±1.0%, and 58.1±1.7%, respectively). Either morphine or BW administered 5 minutes before reperfusion also reduced infarct size when compared with vehicle (Figure 2; 43.6±2.3% and 40.2±2.6% compared with 60.0±1.1%, respectively; P<0.001), an effect that is similar to that observed when morphine or BW were administered before ischemia (Figure 2: 42.9±2.6% and 40.3±2.3%, respectively; P<0.001).
|
|
Western Analysis of GSK With Opioids
Tyr279/216 GSK Phosphorylation
Western blotting for Tyr279/216 phosphorylation for GSK
and GSKß in tissue obtained from ischemic and normal zones of vehicle-, BW-, or morphine-treated groups at 5 minutes of reperfusion were performed (Figure 3, top). No significant changes were found for P-Tyr279 for GSK
in BW- or morphine-treated rats when compared with vehicle (Figure 3, middle; ischemic zone, 113±23 and 108±26 versus 117±25 DU, respectively; normal zone, 105±25 and 99±23 versus 127±26 DU). No significant differences were found for P-Tyr216 GSKß expression in tissue obtained from the ischemic or normal zone in BW- or morphine-treated rats when compared with vehicle (Figure 3, bottom; ischemic zone, 143±12 and 154±10 versus 158±14 DU, respectively; normal zone, 145±12 and 127±7 versus 157±10 DU, respectively).
|
Ser21/9 GSK Phosphorylation
Western blotting for Ser21/9 phosphorylation for GSK
and GSKß in tissue obtained from ischemic and normal zones of vehicle-, BW-, or morphine-treated groups at 5 minutes of reperfusion was determined (Figure 4, top). No differences were seen in P-Ser21 expression for GSK
in either the ischemic or normal zone at 5 minutes of reperfusion in morphine- or BW-treated rats when compared with vehicle (Figure 4, middle; ischemic zone, 53±6 and 38±7 versus 47±8 DU, respectively; normal zone, 63±6 and 43±10 versus 50±16 DU, respectively). In contrast, tissue samples obtained from the ischemic zone at 5 minutes of reperfusion in rats treated with morphine or BW showed a significant elevation of P-Ser9 for GSKß compared with vehicle (Figure 4, bottom; ischemic zone, 181±20 and 178±15 versus 75±17 DU, respectively; P<0.05). No significant differences were found for P-Ser9 GSKß expression in tissue obtained from the normal zone for morphine or BW compared with vehicle (Figure 4, bottom; normal zone, 123±9 and 107±30 versus 88±15 DU, respectively). Prior administration of either wortmannin or rapamycin abrogated morphine-induced phosphorylation of GSKß at Ser9 in ischemic zone tissue [Figure 5; 78±25 and 77±37 DU compared to morphine alone 178±15 DU (P<0.05), respectively].
|
|
Infarct Size Studies With GSK Inhibitors
The GSK inhibitors, SB41 or SB21, reduced infarct size when administered before ischemia when compared with vehicle (Figure 6, 46.6±1.6% and 42.2±1.8% versus 60.0±1.1%, respectively; P<0.001) and SB41 and SB21 also produced a similar reduction in infarct size when administered 5 minutes before reperfusion (Figure 6; 44.8±2.8% and 39.4±0.9%, respectively; P<0.001). Wortmannin, LY294002, or rapamycin given before SB21 had no effect on SB21-induced infarct size reduction (Figure 7; 42.9±2.6%, 42.3±0.8%, and 42.8±2.6%, respectively; P<0.001), whereas wortmannin, LY294002, or rapamycin had no effect on infarct size when given alone as compared with vehicle (Figure 7; 57.0±2.1%, 60.5±1.0%, and 58.1±1.7%, respectively).
|
|
| Discussion |
|---|
|
|
|---|
The results of our study demonstrate that GSK inhibition reduces infarct size as previously found in the preconditioned isolated rat heart, and further extends these findings to show that cardioprotection afforded through GSK inhibition occurs during reperfusion.5 Interestingly, bradykinin, insulin, and urocortin administered at reperfusion also acutely mediate cardioprotection via the PI3K pathway.1619 The importance of PI3K for pharmacological agents to induce cardioprotection likely stems from PI3K-generating phosphatidylinositols (PIPs), which are found to bind to protein pleckstrin homology domains and allow for cellular translocation and protein-protein interactions and/or lipid-protein interactions.20 Additionally, PI3K and TOR have also recently been found to be involved as a trigger of delayed IPC-induced cardioprotection, suggesting the overall importance of these proteins for infarct size reduction.21
TOR has been previously found to regulate p70s6 kinase and eIF-4E BP1, two proteins downstream of TOR that are activated in parallel.12 TOR likely regulated GSK through p70s6, because addition of p70s6 kinase in vitro was found to diminish GSK activity for both GSK isoforms.22 Furthermore, TOR and p70s6 kinase have been suggested to be downstream mediators of PI3K for IPC-induced delayed cardioprotection.21 Although both PI3K and TOR pathways are required for opioid-induced infarct size reduction, it was not discerned in this study whether opioids activate TOR dependently or independently of PI3K. PI3K-independent TOR activation has been shown in human gastrocnemius muscle myoblasts by addition of amino acids, which suggests that these two proteins may be activated independently.23 Further studies will need to be conducted to determine whether PI3K and TOR activation are dependent or independent events that converge at GSK and whether p70s6 kinase is the protein that directly interacts with GSK to result in GSK phosphorylation.
This is also the first study in hearts that has examined opioid-induced modulation of Ser21/9 and Tyr279/216 phosphorylation sites of both GSK isoforms. Our findings that GSKß Ser9 phosphorylation produced by opioids was localized to the ischemic zone is similar to the regional differences of GSKß phosphorylation found during persistent myocardial stunning.24 Furthermore, no differences were found in P-Tyr279/216 for GSK
and GSKß, respectively, when comparing opioid to vehicle-treated animals for the ischemic zones and normal zones within experiments. This would suggest that opioids, similar to insulin-like growth factors or insulin, selectively modulate GSKß only at Ser9.8,9 Our results also differ from those obtained in neuronal cells after cerebral damage that were found to have an increased amount of P-Tyr216 at 3 hours after reperfusion in a middle cerebral artery ischemia/reperfusion model.7 Modulation of Tyr216 may be more important in signaling proapoptotic pathways once salvage of tissue cannot be obtained. The difference between these results and our study is likely the time point selected for investigation of GSK phosphorylation.
Another intriguing finding in this study is the selectivity of opioids to phosphorylate GSKß at Ser9 and not GSK
at Ser21. The selective phosphorylation of GSKß could perhaps involve PKC, which has been previously found to be important in opioid-induced cardioprotection.14 In human neuroblastoma cells, PKC
directly phosphorylates GSKß, which is dependent on cleavage of PKC
by caspase-3.25 In contrast, purified PKC isoforms
1, ß1, ß2, and
, but not
, from sf9 cells can inactivate GSKß, without affecting GSK
.10 However, PKC
may indirectly regulate GSK through PI3K, because induction of a dominant-negative PKC
has previously been found to block phorbol ester and insulin induced activity of PI3K.26 Therefore, the selective PKC isoform responsible for modulating GSK
and GSKß remains unknown and is an interesting area for future studies.
The two selective GSK inhibitors used in this study, SB21 and SB41, are ATP-dependent and have selectivity and preference for GSK inhibition, without inhibition of Akt, MAPK, p70s6 kinase, or PDK1.27 Inhibition of GSK by either selective inhibitor reduced infarct size to a similar extent as opioids, which further supports our hypothesis that opioids reduce infarct size through GSK inhibition. The selectivity of the GSK inhibitor SB21 was further strengthened by the ability of SB21 to reduce infarct size in the presence of either PI3K or TOR inhibitors and suggests that GSK inhibition is a common mediator of infarct size reduction downstream of both PI3K and TOR.
This study is not without potential limitations, because many of the pharmacological agents used may cause nonspecific effects when applied in vivo. However, the use of two different opioids and GSK inhibitors would suggest our results are valid. Furthermore, wortmannin, LY294002, and rapamycin have been found to be selective inhibitors for PI3K and TOR.28 Although the kinase activity of GSK was not measured in this study, a previous report has demonstrated that changes in phosphorylation at Ser9 for GSK produces a decreased activity in isolated rat hearts, with only a 25% reduction of GSKß needed for IPC-induced infarct size reduction to occur, due to the high basal activity of GSKß.5
GSK requires a S/T-X-X-X-S/T-P sequence motif, where either the serine or threonine site is phosphorylated (P), or primed, to allow for GSK to interact with proteins on the other S/T amino acid.29 The pleiotropic nature of GSK suggests multiple downstream targets that could induce cardioprotection by modulating the putative GSK substrates eIF2
,30 cyclin D1,31 glycogen synthase,29 heat shock transcription factor (HSF-1),32 and NF
B33 or yet to be discovered proteins with the GSK sequence motif. These alterations could lead to a change in the cellular state that is more conducive to cardioprotection and are potential future directions of study.
Interestingly, GSKß contributes an essential role for NF
B in the regulation of TNF-
induced apoptosis, because GSKß-null mice are embryonic lethal between E13.5 and E14.5.34 This study also displays the isoform selectivity of GSK to regulate NF-
B function, because liver-induced apoptosis could not be rescued by GSK
. However, in rat primary astrocytes, presence of a constitutively active or phosphorylation-deficient form of GSKß at Ser9 results in astrocyte cell death, abrogates NF-
B activation, and decreases NF-
Bmediated COX-2 expression.33 Hence, the role of GSKß in regulating NF-
B differs between organ systems. Therefore, the cardiovascular role for GSKß regulating NF-
B will need to be investigated; however, the essential role for NF-
B activation in cardiac cells to reduce infarct size in delayed cardioprotection models may suggest that GSKß negatively regulates NF-
B activation as found for astrocytes.33
Immunohistochemical analysis in cerebral cells has shown that both GSK isoforms associate with the rough endoplasmic reticulum, ribosomes, and microtubules, with GSKß, but not GSK
, also associating with the mitochondria.35 The mitochondrial localization of GSKß may suggest that the GSKß pathway may regulate mitochondrial-dependent apoptosis in the heart. Whether the mitochondrial KATP channel (mKATP) interacts with GSKß either directly or indirectly, due to the mitochondrial localization of GSKß, is also a future area of interest. Oxygen-derived free radicals have previously been implicated as a downstream trigger in the protection afforded by the mKATP channel, because the free radical scavenger, N-2-mecaptopropionyl-glycine, abrogates the infarct size reduction afforded by KATP channel openers P-1075, diazoxide, or BMS-191095.15 Generation of oxygen-derived free radicals have been found to activate PI3K and in turn trigger activation of Akt,36 a known upstream modulator of GSK. This suggests a possible link may exist between mitochondrial KATP channel opening, free radical generation, and GSKß modulation through a PI3K-dependent pathway.
In summary, our results show that opioid-induced cardioprotection occurs by GSKß inactivation at Ser9 through PI3K- and TOR-dependent pathways (Figure 8). The ability for SB21 to reduce infarct size in the presence of either PI3K or TOR inhibitors also suggests that GSK is a downstream target of PI3K and TOR. Our results also demonstrate that opioid-induced infarct size reduction is similar to the infarct size reduction produced by two GSK inhibitors when administered just before ischemia or reperfusion.
|
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
in opioid-initiated cardioprotection. Am J Physiol Heart Circ Physiol. 2001; 280: H1346H1353.
-isoform of glycogen synthase kinase-3 from rabbit skeletal muscle is inactivated by p70s6 kinase or MAP kinase-activated protein kinase-1 in vitro. FEBS Lett. 1994; 338: 3742.[CrossRef][Medline]
[Order article via Infotrieve]
: implications for regulation of
phosphorylation. FEBS Lett. 2000; 469: 111117.[CrossRef][Medline]
[Order article via Infotrieve]
. Cell Signal. 1998; 10: 185190.[CrossRef][Medline]
[Order article via Infotrieve]
B signaling. Mol Cell Biol. 2003; 23: 46494662.
ß activation. Nature. 2000; 406: 8690.[CrossRef][Medline]
[Order article via Infotrieve]
in cerebellum mitochondria. J Biochem (Tokyo). 1995; 118: 683685.This article has been cited by other articles:
![]() |
P. S. Pagel, J. G. Krolikowski, P. F. Pratt Jr, Y. H. Shim, J. Amour, D. C. Warltier, and D. Weihrauch Inhibition of Glycogen Synthase Kinase or the Apoptotic Protein p53 Lowers the Threshold of Helium Cardioprotection In Vivo: The Role of Mitochondrial Permeability Transition Anesth. Analg., September 1, 2008; 107(3): 769 - 775. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Murphy and C. Steenbergen Does Inhibition of Glycogen Synthase Kinase Protect in Mice? Circ. Res., August 1, 2008; 103(3): 226 - 228. [Full Text] [PDF] |
||||
![]() |
H. H. Patel and R. S. Ostrom An orphan GPCR finds a home in the heart Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H479 - H481. [Full Text] [PDF] |
||||
![]() |
Y. Nishino, I. G. Webb, S. M. Davidson, A. I. Ahmed, J. E. Clark, S. Jacquet, A. M. Shah, T. Miura, D. M. Yellon, M. Avkiran, et al. Glycogen Synthase Kinase-3 Inactivation Is Not Required for Ischemic Preconditioning or Postconditioning in the Mouse Circ. Res., August 1, 2008; 103(3): 307 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Thotala, D. E. Hallahan, and E. M. Yazlovitskaya Inhibition of Glycogen Synthase Kinase 3{beta} Attenuates Neurocognitive Dysfunction Resulting from Cranial Irradiation Cancer Res., July 15, 2008; 68(14): 5859 - 5868. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. N. Obame, C. Plin-Mercier, R. Assaly, R. Zini, J. L. Dubois-Rande, A. Berdeaux, and D. Morin Cardioprotective Effect of Morphine and a Blocker of Glycogen Synthase Kinase 3{beta}, SB216763 [3-(2,4-Dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione], via Inhibition of the Mitochondrial Permeability Transition Pore J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 252 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gomez, M. Paillard, H. Thibault, G. Derumeaux, and M. Ovize Inhibition of GSK3{beta} by Postconditioning Is Required to Prevent Opening of the Mitochondrial Permeability Transition Pore During Reperfusion Circulation, May 27, 2008; 117(21): 2761 - 2768. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Murphy and C. Steenbergen Mechanisms Underlying Acute Protection From Cardiac Ischemia-Reperfusion Injury Physiol Rev, April 1, 2008; 88(2): 581 - 609. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Zatta, H. Kin, D. Yoshishige, R. Jiang, N. Wang, J. G. Reeves, J. Mykytenko, R. A. Guyton, Z.-Q. Zhao, J. L. Caffrey, et al. Evidence that cardioprotection by postconditioning involves preservation of myocardial opioid content and selective opioid receptor activation Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1444 - H1451. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Gross, A. K. Hsu, and G. J. Gross Delayed cardioprotection afforded by the glycogen synthase kinase 3 inhibitor SB-216763 occurs via a KATP- and MPTP-dependent mechanism at reperfusion Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1497 - H1500. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Gustafsson and R. A. Gottlieb Heart mitochondria: gates of life and death Cardiovasc Res, January 15, 2008; 77(2): 334 - 343. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D.T. Costa, S. V. Pierre, M. V. Cohen, J. M. Downey, and K. D. Garlid cGMP signalling in pre- and post-conditioning: the role of mitochondria Cardiovasc Res, January 15, 2008; 77(2): 344 - 352. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Liem, H. M. Honda, J. Zhang, D. Woo, and P. Ping Past and present course of cardioprotection against ischemia- reperfusion injury J Appl Physiol, December 1, 2007; 103(6): 2129 - 2136. [Abstract] [Full Text] [PDF] |
||||